170227 20260407115449.0 doi 10.1016/j.ejcskn.2026.100781 sideral 148762 ART-2026-148762 eng Aguado, Leyre Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 202 2026 Purpose. This article provides an overview of the scientific content on tirbanibulin 1 % ointment, summarizing key Phase IV results and real-life experiences with tirbanibulin shared by dermatologists across Europe. Materials and Methods. Summary of posters, oral presentation and symposium discussions related to tirbanibulin presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato Oncology (EADO) Congress held between 3rd and 5th of April 2025 in Athens, Greece. Results. We report presented data on the efficacy/effectiveness, safety and tolerability of tirbanibulin 1 % ointment for the treatment of actinic keratosis (AK) on the face, scalp and décolleté. We also collected evidence supporting its use in AK in organ transplant recipients (OTR), solar damaged skin, pigmented AK (PAK), proliferative AK, hypertrophic AK, actinic cheilitis (AC), keratinocyte carcinoma (KC) and lentigo maligna (LM). Conclusions. Overall, data from a Phase IV trial and real-world clinical practice suggest that tirbanibulin is an effective, safe and well-tolerated treatment for AK. Tirbanibulin may also be an option for OTR, patients with PAK, proliferative or hypertrophic AK, and even for conditions such as AC or KC, although the sample size is small in some of these groups and further evidence is needed. Access copy available to the general public Unrestricted info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Borgia, Francesco Broganelli, Paolo Coronel Pérez, Isabel María Dirschka, Thomas Peter Gilaberte, Yolanda Universidad de Zaragoza (orcid)0000-0001-8034-3617 Gualdi, Giulio Hobelsberger, Sarah Luque Varela, Pilar Moyano, Blanca Patel, Girish K. Puig, Susana Savoia, Paola Zalaudek, Iris 1007 183 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Área Dermatología 4 (2026), 6 pp. EJC skin cancer EJC skin cancer 2772-6118 3149629 http://zaguan.unizar.es/record/170227/files/texto_completo.pdf Versión publicada 2101301 http://zaguan.unizar.es/record/170227/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:170227 articulos driver 2026-03-26-14:32:06 ARTICLE